Metformin and Temsirolimus: Metastatic or Unresectable Solid Tumor (Ontario CA)

[Rich66]

http://clinicaltrials.gov/ct2/show/NCT00659568?term=Metformin+cancer&rank=2


Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), April 2008
First Received: April 15, 2008 Last Updated: October 8, 2008 History of Changes (http://clinicaltrials.gov/ct2/archive/NCT00659568)
Sponsored by: London Regional Cancer Program at London Health Sciences Centre
Information provided by: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: NCT00659568
http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif Purpose RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of metformin when given together with temsirolimus in treating patients with metastatic or unresectable solid tumor or lymphoma.


Condition (http://clinicaltrials.gov/ct2/help/conditions_desc) Intervention (http://clinicaltrials.gov/ct2/help/interventions_desc) Phase (http://clinicaltrials.gov/ct2/help/phase_desc) Breast Cancer
Endometrial Cancer
Kidney Cancer
Lung Cancer
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific
Drug: metformin hydrochloride
Drug: temsirolimus
Phase 1




Other Metformin studies:
http://clinicaltrials.gov/ct2/results?term=Metformin+cancer